Efficacy endpoints in oncology clinical trials define what treatment benefit means for a specific cancer study. In this QCast episode, co-hosts Jullia and Tom discuss how endpoints such as overall survival, progression-free survival, objective response rate, disease-free survival, event-free survival, symptom endpoints, and quality-of-life measures each answer a different clinical question. The choice of endpoint affects study design, data collection, interpretation, and how results are communicated.
The episode also looks at where endpoint interpretation can become difficult in practice. A trial may show tumour shrinkage without proving longer survival, or delayed progression without showing that patients live longer. Operational details also matter, including tumour assessment schedules, missed visits, delayed imaging uploads, censoring decisions, and completion rates for patient-reported measures. Getting endpoint selection and collection right helps ensure the evidence supports the claim the trial is trying to make.
🎧 Listen to the Episode:
Key Takeaways
Why Overall Survival is Clear But Not Always Feasible
Overall survival measures time from randomisation to death from any cause, making it a direct and clinically meaningful endpoint. Its objectivity is one reason it is often treated as a strong measure of benefit in oncology. The challenge is that it can require longer follow-up, larger trials, and careful interpretation when patients receive additional treatments after the study therapy.
How Earlier Endpoints Support Oncology Decision-Making
Progression-free survival and objective response rate can help show treatment activity earlier than overall survival. PFS measures time until progression or death, while ORR focuses on tumour shrinkage, often assessed using RECIST criteria in solid tumour trials. These endpoints can be useful, but they should not be overinterpreted as proof of extended survival unless the evidence supports that claim.
Where Endpoint Problems Can Enter the Data
Endpoint reliability depends on how consistently the trial is run. Delayed scans, missed visits, unclear censoring rules, inconsistent progression assessments, and incomplete quality-of-life forms can all affect interpretation. For symptom and quality-of-life endpoints, the questionnaire, timing, missing-data rules, and clinical meaning of the measures need to be planned early so the results can be explained clearly.
Full Transcript
Jullia
Welcome to QCast, the show where biometric expertise meets data-driven dialogue. I’m Jullia.
Tom
I’m Tom, and in each episode, we dive into the methodologies, case studies, regulatory shifts, and industry trends shaping modern drug development.
Jullia
Whether you’re in biotech, pharma or life sciences, we’re here to bring you practical insights straight from a leading biometrics CRO. Let’s get started.
Tom
Today we’re talking about efficacy endpoints in oncology clinical trials. Now these shape what a cancer trial is trying to prove, don’t they?
Jullia
It does. An efficacy endpoint is the measure used to assess whether a treatment is benefiting patients. In oncology, that benefit can mean different things. It might mean patients live longer, their disease does not progress as quickly, their tumours shrink, or their symptoms and quality of life improve.
Tom
So when people say an oncology trial “worked”, it’s the endpoint that tells us what “worked” actually means?
Jullia
Exactly, and that’s why endpoint selection needs care. A trial might show tumour shrinkage, but that does not automatically mean the treatment extends survival. Or it might delay progression, but with toxicity that affects whether the benefit feels meaningful for patients. The endpoint has to match the clinical question.
Tom
Overall survival is often described as the gold standard. Why does it have that status?
Jullia
So overall survival, or OS, measures the time from randomisation to death from any cause. It’s considered the gold standard because it’s direct, clinically meaningful, and relatively objective. Unlike some tumour-based measures, it is less vulnerable to assessment variability.
Tom
But if OS is so clear, why not use it all the time?
Jullia
Because it can make trials longer, larger, and more expensive. Some cancers progress slowly, so waiting for enough survival events can take a long time. OS can also be affected by treatments patients receive after the study treatment, which makes it harder to isolate the effect of the intervention being tested.
Tom
So OS is clear, but it’s not always quick or clean to interpret?
Jullia
Pretty much. While it gives strong evidence, it may not be the most practical endpoint for every setting. That’s one reason oncology trials often use other endpoints, especially where the aim is to understand treatment activity earlier.
Tom
Progression-free survival comes up a lot. What is it actually measuring?
Jullia
Progression-free survival, or PFS, is the time from randomisation until disease progression or death, whichever happens first. It’s commonly used because it can provide results earlier than OS and may require fewer patients. It can also be useful when a treatment is expected to delay tumour growth rather than immediately show an effect on survival.
Tom
Can you give a practical example of where PFS becomes tricky?
Jullia
A common issue is the tumour assessment schedule. If one site scans patients later than planned, progression might be recorded later than it should have been. If another site scans exactly on schedule, those patients may appear to progress earlier simply because the assessment happened on time. That can introduce bias if it isn’t monitored carefully.
Tom
So it also depends on operational discipline.
Jullia
It does. If PFS is a primary endpoint, scan timing, missed assessments, censoring rules, and progression definitions all need to be managed carefully. A delayed scan or imaging upload can quickly become an endpoint issue.
Tom
A common misunderstanding is that PFS means patients live longer. Is that always true?
Jullia
Not really. A longer PFS means the disease has not progressed, or the patient has not died within the endpoint definition for a longer period. But it does not automatically prove an improvement in overall survival. Therefore, wording matters when results are discussed since “progression-free” can sound like a survival claim if it is not explained clearly. The wording needs to separate tumour control, delayed progression, and extended life.
Tom
What about tumour response? Objective response rate comes up a lot, especially in earlier studies.
Jullia
Objective response rate, or ORR, is the proportion of patients whose tumours shrink by a defined amount for a defined period. It is often assessed using RECIST criteria in solid tumour trials. ORR can give an earlier signal of antitumour activity, especially in single-arm trials or settings with limited treatment options.
Tom
And RECIST is the framework for deciding whether that shrinkage counts?
Jullia
Yes. RECIST stands for Response Evaluation Criteria in Solid Tumours. It sets rules for selecting lesions, measuring them, and categorising response as complete response, partial response, stable disease, or progressive disease.
Tom
Could you give a concrete example?
Jullia
So suppose a patient has several measurable lesions on a baseline CT scan. The team selects target lesions, measures them, and compares later scans with that baseline. A partial response requires enough reduction in tumour measurements. Progressive disease may involve enough growth, new lesions, or progression of non-target disease.
Tom
So ORR can show activity earlier. But what does it miss?
Jullia
It focuses on tumour shrinkage. A treatment may slow or stop growth without enough shrinkage to count as a response. ORR also does not tell us how long the response lasts, which is why duration of response is often reported alongside it.
Tom
Where do disease-free survival and event-free survival fit in here?
Jullia
They’re time-to-event endpoints, but they’re used in different treatment settings. Disease-free survival, or DFS, is often used after definitive treatment, such as surgery or radiotherapy, and measures time until recurrence or death. Event-free survival, or EFS, is more often used before surgery in neoadjuvant settings, where events may include progression, discontinuation, or death.
Tom
So the pathway around surgery changes the endpoint.
Jullia
Exactly. In an adjuvant trial, the question may be whether treatment prevents recurrence. In a neoadjuvant trial, it may be whether treatment before surgery improves response or delays an event before definitive treatment.
Tom
But with so many endpoint options, couldn’t a sponsor just choose the one most likely to show a positive result?
Jullia
Well that’s why the endpoint has to be justified before the trial starts. The protocol should define the primary and secondary endpoints, how they will be measured, and how missing or incomplete data will be handled. The choice needs a clinical rationale.
Tom
Oncology endpoints can sound very imaging-heavy, but patient experience matters too, yes?
Jullia
Absolutely. Health-related quality of life can show whether patients feel and function better during treatment. It is often used as a secondary endpoint, especially where treatments have similar effects on disease control but different toxicity profiles. Symptom endpoints can also support the clinical picture when tumour measurements do not tell the full story.
Tom
What makes symptom assessment difficult?
Jullia
Symptoms can be influenced by several things at once. Pain or fatigue might relate to tumour progression, treatment toxicity, another condition, or a later therapy. Missed assessments and open-label trial designs can also make interpretation harder.
Which is why these endpoints need careful planning as well. The questionnaire, timing, missing-data rules, and interpretation need to be thought through early. If a composite symptom endpoint combines measures that mean very different things, the result may be difficult to explain.
Tom
What should teams watch as the trial is running?
Jullia
Just the usual everyday details. These can be anything from missed visits, delayed scans, inconsistent progression assessments, unclear censoring decisions, and completion rates for quality-of-life forms. By the time the final analysis starts, those issues are often much harder to fix.
The endpoint has to be collected in a way that supports the claim the trial wants to make. OS, PFS, ORR, DFS, EFS, symptom endpoints, and quality-of-life measures each answer a different question. Earlier endpoints can be valuable, but the interpretation has to stay close to what was actually measured.
Tom
So endpoint choice is really a design decision, a data decision, and a communication decision all at once.
Jullia
That’s right. OS remains the most direct survival endpoint, but it is not always feasible or sufficient on its own. Other endpoints can add useful evidence, as long as they fit the treatment goal, the disease setting, and the data the trial can realistically collect.
Jullia
With that, we’ve come to the end of today’s episode on efficacy endpoints in oncology clinical trials. If you found this discussion useful, don’t forget to subscribe to QCast so you never miss an episode and share it with a colleague. And if you’d like to learn more about how Quanticate supports data-driven solutions in clinical trials, head to our website or get in touch.
Tom
Thanks for tuning in, and we’ll see you in the next episode.
About QCast
QCast by Quanticate is the podcast for biotech, pharma, and life science leaders looking to deepen their understanding of biometrics and modern drug development. Join co-hosts Tom and Jullia as they explore methodologies, case studies, regulatory shifts, and industry trends shaping the future of clinical research. Where biometric expertise meets data-driven dialogue, QCast delivers practical insights and thought leadership to inform your next breakthrough.
Subscribe to QCast on Apple Podcasts or Spotify to never miss an episode.
